Medicine recalls
|
| |
| Canada: Recall: APO-Candesartan 16 mg |
| |
Apotex Inc. initiated the recall of one additional lot of APO-Candesartan 16mg (lot no.: KW0445) due to out of specification results during stability testing for CAD-II impurity.
Please refer to the following website in Health Canada for details:
http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/../53251r-eng.php
In Hong Kong, Apo-Candesartan 16mg is not a registered pharmaceutical product. Related news about the recalls of Apotex products had been issued by Health Canada, and was posted on the Drug Office website on 13, 18 and 20 April 2015. In response to the above announcements, three batches of Apo-Fluoxetine Cap 20mg (HK-41383) (lot no.: KT8932, KZ8595 and ME3862), one batch of Apo-Pregabalin Cap 50mg (HK-62682) (lot no.: KW3889), and one batch of Apo-Verap SR Tab 240 mg (HK-59212) (lot no.: KL7884) had been recalled by the registration certificate holder Hind Wing Co Ltd. in Hong Kong. So far, the Department of Health (DH) has not received any adverse drug reaction reports related to Apotex products. The DH has launched enquiries to Health Canada for details of the incidents, and the replies are pending. The DH will continue to remain vigilant about the progress of the incidents.
Ends/ Tuesday, May 05, 2015
Issued at HKT 15:00
|
| |
|
